Peripheral coldness adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 13,545 adverse event reports that record the MedDRA preferred term Peripheral coldness. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 689 reports in the 12 months to June 2026 and 710 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 812 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 689 (0.1%) record this term. Reports for female patients were 58.3% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 145 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Peripheral coldness name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		27
Aclasta		29
Actemra	Interleukin-6 receptor antagonist	65
Afinitor	Kinase inhibitor	45
Aimovig		42
Alemtuzumab	CD52-directed cytolytic antibody	47
Allopurinol	Xanthine oxidase inhibitor	25
Ambrisentan	Endothelin receptor antagonist	38
Amlodipine	Calcium channel blocker	148
Ampyra	Potassium channel blocker	77
Anticoagulant Sodium Citrate	Anti-coagulant	72
Aripiprazole	Atypical antipsychotic	27
Aspirin	Nonsteroidal anti-inflammatory drug	86
Atenolol	beta-Adrenergic blocker	109
Atorvastatin		51
Aubagio	Pyrimidine synthesis inhibitor	59
Avastin	Vascular endothelial growth factor inhibitor	34
Avonex	Interferon beta	135
Ayvakit	Kinase inhibitor	30
Baclofen	gamma-Aminobutyric acid-ergic agonist	35
Bisoprolol	beta-Adrenergic blocker	79
Bisoprolol fumarate	beta-Adrenergic blocker	33
Byetta	GLP-1 receptor agonist	69
Cabometyx	Kinase inhibitor	29
Capecitabine	Nucleoside metabolic inhibitor	64
Carbidopa levodopa	Aromatic amino acid	37
Carboplatin	Platinum-based drug	48
Carvedilol	alpha-Adrenergic blocker	54
Chantix	Partial cholinergic nicotinic agonist	25
Ciprofloxacin	Fluoroquinolone antibacterial	117
Clopidogrel	P2Y12 platelet inhibitor	50
Coreg	alpha-Adrenergic blocker	32
Cosentyx	Interleukin-17A antagonist	57
Coumadin		25
Crestor	HMG-CoA reductase inhibitor	48
Cyclophosphamide	Alkylating drug	32
Cymbalta		86
Dexamethasone	Corticosteroid	52
Diclofenac	Nonsteroidal anti-inflammatory drug	30
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	45
Digoxin	Cardiac glycoside	35
Dupixent	Interleukin-4 receptor alpha antagonist	101
Eliquis	Factor Xa inhibitor	110
Enbrel	Tumor necrosis factor blocker	231
Entresto	Angiotensin 2 receptor blocker	138
Entyvio	Integrin receptor antagonist	29
Ergocalciferol	Provitamin D2 compound	36
Firdapse	Potassium channel blocker	36
Fluorouracil	Nucleoside metabolic inhibitor	48
Forteo	Parathyroid hormone analog	82
Furosemide	Loop diuretic	88
Gabapentin	Anti-epileptic agent	54
Gilenya	Sphingosine 1-phosphate receptor modulator	132
Hemangeol	beta-Adrenergic blocker	178
Humalog	Insulin analog	36
Humira		393
Hydrocortisone	Corticosteroid	35
Ibrance	Kinase inhibitor	57
Ibuprofen	Nonsteroidal anti-inflammatory drug	44
Imbruvica	Kinase inhibitor	53
Indapamide	Thiazide-like diuretic	43
Inflectra	Tumor necrosis factor blocker	54
Infliximab	Tumor necrosis factor blocker	51
Ixazomib	Proteasome inhibitor	26
Jakafi	Janus kinase inhibitor	64
Kesimpta	CD20-directed cytolytic antibody	65
Lamictal	Anti-epileptic agent	29
Lamotrigine	Anti-epileptic agent	33
Lansoprazole	Proton pump inhibitor	26
Lenalidomide	Thalidomide analog	35
Levaquin		44
Levofloxacin	Fluoroquinolone antibacterial	75
Levothyroxine		29
Lipitor	HMG-CoA reductase inhibitor	53
Lisinopril	Angiotensin converting enzyme inhibitor	48
Lorazepam	Benzodiazepine	56
Losartan	Angiotensin 2 receptor blocker	27
Lyrica		271
Meloxicam	Nonsteroidal anti-inflammatory drug	25
Metformin	Biguanide	56
Methotrexate	Folate analog metabolic inhibitor	136
Methylprednisolone	Corticosteroid	30
Methylprednisolone sodium succinate	Corticosteroid	31
Metoprolol	beta-Adrenergic blocker	99
Metoprolol succinate	beta-Adrenergic blocker	58
Metoprolol tartrate	beta-Adrenergic blocker	28
Metronidazole	Nitroimidazole antimicrobial	26
Mirtazapine		42
Mounjaro	GLP-1 receptor agonist	47
Neurontin		48
Ocrevus	CD20-directed cytolytic antibody	53
Omeprazole	Proton pump inhibitor	65
Opsumit	Endothelin receptor antagonist	37
Oxaliplatin	Platinum-based drug	73
OxyContin	Opioid agonist	30
Ozempic	GLP-1 receptor agonist	34
Paclitaxel	Microtubule inhibitor	37
Pegasys	Interferon alpha	45
Plavix	P2Y12 platelet inhibitor	30
Pomalyst	Thalidomide analog	43
Pradaxa	Direct thrombin inhibitor	47
Prednisone	Corticosteroid	62
Pregabalin		28
Prolia	RANK ligand inhibitor	79
Propranolol	beta-Adrenergic blocker	83
Propranolol hydrochloride	beta-Adrenergic blocker	36
Ramipril	Angiotensin converting enzyme inhibitor	125
Rebif	Interferon beta	62
Remicade	Tumor necrosis factor blocker	94
Remodulin	Prostacycline vasodilator	41
Repatha	PCSK9 inhibitor	58
Revlimid	Thalidomide analog	276
Ribavirin	Nucleoside analog antiviral	34
Rinvoq	Janus kinase inhibitor	36
Rituxan	CD20-directed cytolytic antibody	31
Rituximab	CD20-directed cytolytic antibody	77
Sandostatin	Somatostatin analog	62
Sandostatin LAR Depot		43
Simvastatin	HMG-CoA reductase inhibitor	93
Skyrizi	Interleukin-23 antagonist	28
Spironolactone	Aldosterone antagonist	44
Strattera	Norepinephrine reuptake inhibitor	61
Synthroid	l-Thyroxine	60
Tecfidera		93
Telmisartan	Angiotensin 2 receptor blocker	31
Toprol-Xl		33
Tramadol		31
Trulicity	GLP-1 receptor agonist	27
Tylenol	Expectorant	34
Tysabri	Integrin receptor antagonist	196
Ultravist	Radiographic contrast agent	33
Uptravi	Prostacyclin receptor agonist	31
Valsartan	Angiotensin 2 receptor blocker	37
Vedolizumab	Integrin receptor antagonist	47
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	36
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	27
Vyvanse	Central nervous system stimulant	52
Xarelto	Factor Xa inhibitor	46
Xeljanz	Janus kinase inhibitor	127
Xeloda	Nucleoside metabolic inhibitor	34
Xolair	Anti-IgE	40
Xtandi	Androgen receptor inhibitor	33
Xyrem	Central nervous system depressant	110
Zejula	Poly(ADP-Ribose) polymerase inhibitor	31
Zometa		44

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 58 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Peripheral coldness name, in order of name
Class	Reports with this term
Aldosterone antagonist	56
alpha-Adrenergic blocker	109
Angiotensin 2 receptor blocker	309
Angiotensin converting enzyme inhibitor	189
Anti-coagulant	90
Anti-epileptic agent	155
Anti-IgE	61
Atypical antipsychotic	184
Benzodiazepine	120
beta-Adrenergic blocker	770
Biguanide	99
Bisphosphonate	85
Calcium channel blocker	168
CD20-directed cytolytic antibody	248
CD52-directed cytolytic antibody	63
Central nervous system depressant	139
Central nervous system stimulant	137
Corticosteroid	297
Endothelin receptor antagonist	115
Factor Xa inhibitor	185
Fluoroquinolone antibacterial	198
Folate analog metabolic inhibitor	154
GLP-1 receptor agonist	220
HMG-CoA reductase inhibitor	233
Insulin analog	82
Integrin receptor antagonist	272
Interferon beta	202
Interleukin-17A antagonist	57
Interleukin-4 receptor alpha antagonist	101
Interleukin-6 receptor antagonist	80
Janus kinase inhibitor	229
Kinase inhibitor	401
l-Thyroxine	99
Loop diuretic	113
Microtubule inhibitor	54
Nonsteroidal anti-inflammatory drug	278
Norepinephrine reuptake inhibitor	64
Nucleoside metabolic inhibitor	181
Opioid agonist	186
P2Y12 platelet inhibitor	118
Parathyroid hormone analog	94
PCSK9 inhibitor	69
Phosphodiesterase 5 inhibitor	59
Platinum-based drug	138
Poly(ADP-Ribose) polymerase inhibitor	57
Potassium channel blocker	113
Prostacycline vasodilator	114
Proton pump inhibitor	152
Pyrimidine synthesis inhibitor	76
RANK ligand inhibitor	79
Serotonin and norepinephrine reuptake inhibitor	135
Serotonin reuptake inhibitor	137
Sodium-Glucose cotransporter 2 inhibitor	63
Somatostatin analog	81
Sphingosine 1-phosphate receptor modulator	146
Thalidomide analog	358
Tumor necrosis factor blocker	493
Vascular endothelial growth factor inhibitor	50

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Peripheral coldness, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Peripheral coldness
Age	Reports	Share
Under 2	197	1.5%
2 to 11	221	1.6%
12 to 17	242	1.8%
18 to 44	2,058	15.2%
45 to 64	3,346	24.7%
65 to 74	1,865	13.8%
75 and over	1,321	9.8%
Age not given	4,295	31.7%

Sex of the patient in the reports that record Peripheral coldness
Sex	Reports	Share
Female	7,901	58.3%
Male	4,671	34.5%
Unknown or not given	973	7.2%

Age and sex are as the report gives them. 58.1% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Peripheral coldness: adverse event reports that record this term. https://reportedreactions.com/reaction/peripheral-coldness/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Peripheral coldness mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page